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electrocardiogram at the time of presentation to the emergency department (ED).Background Copeptin is secreted from the pituitary early in the course of AMI.Methods This was a 16-site study in 1,967 patients with chest pain presenting to an ED within 6 hours of pain onset. Baseline
demographic characteristics and clinical data were collected prospectively. Copeptin levels and a contemporary
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predictive value (all p < 0.0001).Conclusions Adding copeptin to cTnI allowed safe rule out of AMI with a negative predictive value >99% in patients
presenting with suspected acute coronary syndromes. This combination has the potential to rule out AMI in
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151An estimated 6 to 8 million patients present to US emergency
departments (EDs) each year with suspected acute coronary
syndromes (ACS) (1). In this population, biomarkers are
a critical component of their evaluation. Although an eleva-
tion of cardiac troponin (cTn) with a rising and/or falling
pattern in the setting of suspected ACS represents the gold
standard for a non–ST elevation myocardial infarction
(NSTEMI) diagnosis, the absence of an elevated value at the
time of presentation does not rule out an acute ischemic event.
Because symptoms are nonspeciﬁc, a method to rapidly rule
out AMI would be helpful for early ED disposition. A
biomarker that provides additional value to cTn would
improve resource allocation and clinical decision making,
particularly if it could be assessed at the time of presentation.
Arginine vasopressin (AVP) is responsible for a variety of
hemodynamic functions that contribute to vascular tone and
the maintenance of blood volume. Despite a theoretical
diagnostic role in cardiovascular disease, its clinical appli-
cation as a useful laboratory test has been limited by its short
half-life in the circulation. Copeptin (the C-terminal portion
of the AVP precursor peptide) is more stable and provides
an easily measured surrogate biomarker for AVP release
(2,3). After acute myocardial infarction (AMI), circulating
copeptin levels rise to peak values rapidly and then decline
over the next 2 to 5 days (4).
Measurement of copeptin has been reported to rapidly
exclude AMI in patients presenting with suspected ACS
(5,6). In 1 study of 487 consecutive ED patients (5),
copeptin was elevated (>14 pmol/l) within 4 h of symptom
onset, despite undetectable levels of cardiac troponin T
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152Good Clinical Practice regulations, and all 16 study sites
received local institutional review board or ethics committee
approval. All patients provided written informed consent for
participation.
Patients were seen and evaluated in the ED of the
participating trial sites by emergency physicians who per-
formed their usual standard of care assessment and treat-
ment. For each patient enrolled in the study, the emergency
physicians, blinded to the investigational marker results,
documented their impression of: 1) the likelihood that the
patient was experiencing an ACS; and 2) the likelihood
that the patient was experiencing an AMI. These assess-
ments were made on 2 separate visual analog scales (VAS),
assigning a value of 0% to 100% clinical diagnostic certainty.
This VAS scoring was performed at 2 different time points
for each patient: the ﬁrst scoring was done within 15 min of
the physician seeing and evaluating the patient and before
seeing the ﬁrst troponin results; the second scoring was
completed after the initial troponin result was reported.
Samples were obtained at the time of presentation (0 h) and
then 2, 6, and 24 h later if the patient was still hospitalized.
Local site biomarker values were used to guide patient
management as per usual care. In addition, the blood was
centrifuged, and plasma was stored at –60C and later
analyzed at the study core laboratory. Patients were followed
up via telephone or medical records for the occurrence of
death, AMI, and/or revascularization within the follow-up
time frames of 30, 90, and 180 days.
Gold standard/adjudicated ﬁnal diagnosis. After the
30-day follow-up was completed, each case report form was
reviewed by at least 2 board-certiﬁed cardiologists, who each
made a determination of the ﬁnal diagnosis. In the event that
the cardiologist reviewers didnot agree, the casewas adjudicated
by theEndpointsCommittee.All evaluationswere reviewed for
consistency by the Endpoints Committee. The ﬁnal clinical
diagnosis was based on predetermined guidelines (see Online
Appendix for details). All ﬁnal diagnoses were assigned to 1
of the following 6 categories: 1) ST-segment elevation
myocardial infarction (STEMI); 2) NSTEMI; 3) unstable
angina pectoris; 4) cardiovascular disease but non-ACS
etiology; 5) noncardiac diagnosis; and 6) unclassiﬁed cause of
chest pain. The local cardiac troponin values and the local cutoff
values in use at that center were used for this determination.
Investigational assays of cardiac biomarkers. Subsequent
to local measurement, cardiac troponin I (cTnI) was
also measured in the core laboratory at the University of
Maryland (R.C., Principal Investigator) with the cTnI Ultra
assay on an ADVIA Centaur XP system (Siemens Health-
care Diagnostics, Norwood, Massachusetts). The assay
detection limit as described by the manufacturer was 6 ng/l,
measuring range was 6 to 50,000 ng/l, 99th percentile was
40 ng/l, and 10% coefﬁcient of variation was 30 ng/l.
Ethylenediaminetetraacetic acid plasma concentrations
of copeptin were measured in the core laboratory on a Kryp-
tor Compact platform (BRAHMS GmbH, Hennigsdorf,
Germany). The assay detection limit as described by themanufacturer was 4.8 pmol/l. The direct measuring range was
4.8 to 500 pmol/l (up to 1,200 pmol/l with automatic dilution)
with a functional assay sensitivity (lowest value with an
interassay coefﬁcient of variation <20%) of <12.0 pmol/l.
Study end points. The CHOPIN primary hypothesis was
whether a copeptin level <14 pmol/l on the initial blood
draw in combination with cTnI and an electrocardiogram
(ECG) would rule out the diagnosis of AMI in patients with
symptoms of ACS. For the centralized cTnI values, the 99th
percentile (40 ng/l) was used as a cutoff. For copeptin, based
on review of the previous literature (5,6), a rule-out cutoff
value of 14 pmol/l was pre-speciﬁed in the protocol.
Additional secondary hypotheses examined the utility of
copeptin in the evaluation of ACS. A complete listing of the
secondary hypotheses can be found in the Methods section
of the Online Appendix.
Statistical analysis. Values are expressed as mean  SD,
non-normally distributed continuous variables are expressed
as medians and interquartile range (IQR), or counts and
percentages, as appropriate. Group comparisons of contin-
uous variables were performed by using the Student t test,
analysis of variance models, or the Kruskal-Wallis test, as
appropriate. Biomarker data were log-transformed if nec-
essary. Categorical data were compared by using the Pear-
son chi-square test. All statistical tests were 2-tailed, and a
2-sided p value of 0.05 was considered signiﬁcant.
For a simple model of time to diagnostic decision of AMI
versus no AMI, we assumed that patients with an STEMI
(immediate rule-in based on ECG) or negative copeptin and
cTnI (immediate rule-out) could be identiﬁed within 1 h
after presentation, whereas all others would need at least a 3-
h interval until the second cTnI could be determined.
Average time to decision was calculated by taking the mean
time to decision for all patients.
Cox proportional hazards regressionwas used to analyze the
effect of risk factors on survival in univariable and multivari-
able analyses (7). The assumptions of proportional hazard
were tested via scaled Schoenfeld residuals for all variables.
None of the variables showed a signiﬁcant deviation from the
proportional hazards assumption. Log-transformed values of
copeptin and cTnI were evaluated in a Cox regression model
to determine the contribution of copeptin over and above that
of cTnI by using the likelihood ratio chi-square test for nested
models. The predictive value of each model was assessed by
using the model likelihood ratio chi-square statistic. The
concordance index (c index) is given as an effect measure. It is
equivalent to the concept of area under the curve (AUC)
adopted for binary outcomes. For multivariable models,
a bootstrap-corrected version of the c index is given. Survival
curves plotted according to the Kaplan-Meier method were
used for illustrative purposes. Time-dependent receiver-
operating characteristic curves and time-dependent AUC
values were determined from censored survival data by using
the Kaplan-Meier method (8).
According to consensus recommendations, a diagnosti-
cally relevant rise or fall in cTnI was deﬁned as a change
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153>2.77 times the SD from the precision curve of the cTnI
assay as reported by the manufacturer (9); that is, a rise or fall
was considered positive if there was a change >60% for
patients with a maximum cTnI value <20 ng/l, >30% for
change of maximum cTnI between 20 and 40 ng/l, and
>20% for cTnI >40 ng/l.
The statistical analyses were performed by using R ver-
sion 2.5.1 (Hmisc and Design Libraries, ROCR, R Foun-
dation for Statistical Computing, Vienna, Austria) and
SPSS version 16.0 (IBM SPSS Statistics, IBM Corporation,
Armonk, New York).
The data management center (VA San Diego) was res-
ponsible for data quality control and statistical analysis. The
academic principal investigators of the trial hold an inde-
pendent copy of the trial database and were able to perform
independent statistical analysis.
Results
A total of 2,071 patients were recruited. Of these, 63
presented>6 h after symptomonset, and 8 did not have a gold
standard diagnosis documented. Of the remaining, 33 had
either amissing copeptin or cTnI value at time of presentation
(18 missing each, including 3 missing both). Therefore, our
ﬁnal dataset contained 1,967 eligible patients. Of these, 75%
(n¼ 1,474) presented within 3 h of symptom onset. The ﬁnal
adjudicated diagnosis was STEMI in 40 (2.0%), NSTEMI in
116 (5.9%), unstable angina in 127 (6.5%), cardiovascular
non-ACS in 413 (21.0%), a noncardiac diagnosis in 599
(30.5%), and an unclassiﬁed cause of chest pain in 672
(34.2%). Concordance between ﬁnal adjudicated and ﬁnal
ED diagnosis was seen in 96.7% of patients. Follow-up blood
samples were available in 1,802 patients at 2 h; 1,464 patients
at 6 h; and 567 patients at 24 h. Baseline characteristics are
summarized in Table 1.
Copeptin and cTnI by diagnostic categories and time
since symptom onset. Median cTnI and copeptin concen-
trations at time of presentation were higher in patients with
AMI (0.181 vs. 0.003 mg/l for cTnI and 19.9 vs. 9.2 pmol/l for
copeptin; both p < 0.001, Kruskal-Wallis). Copeptin levels
were elevated in STEMI and NSTEMI patients who had
normal cTnI values at the time of presentation (cTnI<40 ng/l,
99th percentile): median copeptin concentration in initial
cTnI-negative STEMI patients was 129.2 pmol/l (IQR: 33.4
to 184.4; n¼ 13); inNSTEMI, it was 17.8 pmol/l (IQR: 8.1 to
28.8; n¼ 19). In patientswithother diagnoses, itwas 8.7 pmol/l
(IQR:<5 to 16.2; n¼ 1,627). For patients with elevated cTnI
at presentation, median values were 23.0 pmol/l (IQR: 9.5 to
136.5; n¼ 27), 17.4pmol/l (IQR: 8.4 to60.9; n¼ 97), and14.9
pmol/l (IQR: 8.2 to 42.7; n¼ 184) for STEMI,NSTEMI, and
other diagnosis, respectively (Fig. 1).
Figure 2 displays the median values of copeptin and cTnI
for time since symptom onset according to main diagnosis
(AMI vs. other), combining all data available from the blood
draws at time of presentation, and at 2, 6, and 24 h later.
Although copeptin levels slowly decreased with increasingtime from symptom onset, cTnI levels rose, with a peak at
8 to 10 h. Median values for patients without AMI stayed
ﬂat for both copeptin and cTnI.
Primary hypothesis: rule out AMI by using copeptin and
cTnI. Figure 3 illustrates the combined performance of ﬁrst
ECG plus cTnI and copeptin measured at time of presen-
tation. For patients with a nondiagnostic ECG (i.e., those
without STEMI), initially normal cTnI (<99th percentile/
<40 ng/l), and negative copeptin (<14 pmol/l) (n ¼ 1,143
[58%]), the negative predictive power (NPV) was 99.2%
(95% conﬁdence interval [CI]: 98.5 to 99.6). The positive
predictive power (PPV) for patients with either elevated
cTnI or copeptin (n ¼ 784) was 13.6% (95% CI: 11.4 to
16.2). Sensitivity for the dual marker combination was
92.2% (95% CI: 85.9 to 95.9), and speciﬁcity was 62.6%
(95% CI: 60.4 to 64.8). Ten of the 19 NSTEMI patients
(53%) who did not have an elevated cTnI at the time of
presentation were copeptin positive.
Negative copeptin at presentation in combination with
a negative cTnI ruled out 58% of all patients without need
for a second blood draw. Assuming a 3-h interval until the
second cTnI could be determined, the addition of copeptin
to the initial cTnI and ECG would reduce the time to
decision for AMI diagnosis from an average of 2.96 to
1.80 h (43%).
Figure 4 illustrates the incremental value of copeptin in
groups stratiﬁed based on the physician estimate of AMI
probability after the ﬁrst cTnI result was available. Low
risk was deﬁned as a value of 0% to 5%, intermediate
risk from 5% to 25%, and high risk as >25%. Bars in the
graphic represent the observed risk of AMI in the study.
Of 466 patients deemed intermediate risk by emergency
physicians according to VAS assessment, 294 (63%) had
a copeptin level <14 pmol/l. For this group, the AMI risk
was signiﬁcantly lower compared with that of patients with
copeptin levels >14 pmol/l (2.0% vs. 9.3%; p < 0.01), and
the AMI risk was comparable to that of VAS low-risk
patients (observed AMI risk 2% for both: 16 of 816 for
the low-risk group and 6 of 294 for the intermediate-risk
group with AMI). The NPV for patients with a negative
copeptin and negative cTnI value in patients with
VAS <25% was 99.6%, and for patients with VAS <5%, it
was 99.8%. These data suggest that a low copeptin level is
associated with low risk even if physicians think that AMI is
possible with a pretest likelihood of up to 25%.
Diagnosis after second cTnI sample. To better under-
stand the added value of copeptin, we examined the overall
performance of cTnI at time of presentation, of cTnI 6 h later,
and of ﬁrst ECG when used per guideline recommendations.
This performance was compared with that of the same algo-
rithm but also including copeptin measured at time of
presentation for early rule out. A patient was deﬁned as “serial
cTnI positive” if a rise or fall in cTnI between the time of
presentation and 6 h later was observed (see Methods
for details), and the cTnI value was >99th percentile on at
least 1 occasion. All other patients were counted as “serial
Table 1 Patient Characteristics According to AMI Diagnosis
Variables N valid All Patients No AMI (n ¼ 1,811*) AMI (n ¼ 156*) p Value
Demographics
Male 1,967 1,118 (56.8) 1,001 (55.3) 117 (75) <0.0001
Hispanic ethnicity 1,959 106 (5.4) 98 (5.4) 8 (5.1) 1.0000
Race 1,967 0.2664
Asian 47 (2.4) 44 (2.4) 3 (1.9)
Black 766 (38.9) 716 (39.5) 50 (32.1)
White 1,024 (52.1) 931 (51.4) 93 (59.6)
Other/unknown 130 (6.6) 120 (6.6) 10 (6.4)
Age (yrs) 1,967 56.412.8 56  12.8 61.6  11.4 <0.0001
Vital signs at presentation
Heart rate (beats/min) 1,962 81.3  19.1 81.1  19.1 83.8  19.7 0.0941
Temperature (C) 1,841 36.6  0.4 36.6  0.4 36.6  0.5 0.7666
Systolic BP (mm Hg) 1,960 142.3  26.9 142  26.6 145.5  30.3 0.0886
Diastolic BP (mm Hg) 1,960 80.6  16.1 80.3  15.8 84  19.1 0.0094
Respiratory rate (per min) 1,955 18.5  3.5 18.4  3.3 19.5  5.1 0.0032
Pulse (beats/min) 1,942 97.9  2.9 97.9  2.8 97.7  3.8 0.9790
BMI (kg/m2) 1,824 30.7  7.7 30.8  7.9 29.8  6.2 0.2214
Ischemic equivalents
Symptoms at presentation 1,960 1,579 (80.6) 1,449 (80.2) 130 (84.4) 0.2431
Time since symptom onset (h) 1,950 2.1  1.4 2.1  1.4 2.1  1.4 0.8007
Time since symptom onset 3–6 h 1,950 476 (24.4) 438 (24.4) 38 (24.8) 0.9219
Symptom onset, sudden 1,904 1,409 (74) 1,306 (74.4) 103 (69.6) 0.2055
Symptoms occurrence, intermittent 1,885 866 (45.9) 806 (46.4) 60 (40.5) 0.1974
Symptom duration 1,848 0.2004
<2 min 101 (5.5) 98 (5.8) 3 (2)
2–10 min 248 (13.4) 229 (13.5) 19 (12.8)
10–30 min 288 (15.6) 267 (15.7) 21 (14.2)
>30 min 1,211 (65.5) 1,106 (65.1) 105 (70.9)
Physical examination
Bilateral rales 1,929 83 (4.3) 73 (4.1) 10 (6.5) 0.2091
Wheezing 1,937 101 (5.2) 93 (5.2) 8 (5.2) 1.0000
S3 1,881 43 (2.3) 36 (2.1) 7 (4.6) 0.0779
Cardiac risk factors
Hypertension 1,956 1,366 (69.8) 1,248 (69.3) 118 (76.1) 0.0830
CAD family history 1,512 685 (45.3) 625 (44.8) 60 (51.7) 0.1740
Diabetes mellitus 1,959 565 (28.8) 502 (27.8) 63 (40.4) 0.0012
Tobacco 1,966 0.0020
Current 651 (33.1) 600 (33.1) 51 (32.7)
Ever 484 (24.6) 428 (23.6) 56 (35.9)
Never 831 (42.3) 782 (43.2) 49 (31.4)
Hypercholesterolemia 1,894 1,059 (55.9) 960 (54.9) 99 (68.3) 0.0017
Cocaine 1,959 0.6007
Current 125 (6.4) 118 (6.5) 7 (4.5)
Ever 187 (9.5) 171 (9.5) 16 (10.3)
Never 1,647 (84.1) 1,514 (84) 133 (85.3)
Renal insufﬁciency 1,699 140 (8.2) 124 (7.9) 16 (12.3) 0.0947
AMI 1,929 538 (27.9) 478 (26.9) 60 (38.7) 0.0027
CAD 1,927 741 (38.5) 655 (36.9) 86 (56.2) <0.0001
Revascularization 1,936 575 (29.7) 513 (28.8) 62 (40.8) 0.0029
Heart failure 1,941 332 (17.1) 305 (17.1) 27 (17.6) 0.8235
COPD 1,948 212 (10.9) 191 (10.6) 21 (13.6) 0.2793
Ventricular tachycardia 1,931 60 (3.1) 54 (3) 6 (4) 0.4623
Cardiac arrest 1,954 56 (2.9) 50 (2.8) 6 (3.9) 0.4461
Atrial ﬁbrillation 1,933 192 (9.9) 179 (10.1) 13 (8.5) 0.6721
Peripheral vascular disease 1,930 109 (5.6) 92 (5.2) 17 (11.1) 0.0053
Stroke 1,958 195 (10) 177 (9.8) 18 (11.7) 0.4822
AICD pacemaker 1,963 143 (7.3) 133 (7.4) 10 (6.4) 0.7502
Continued on the next page
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Table 1 Continued
Variables N valid All Patients No AMI (n ¼ 1,811*) AMI (n ¼ 156*) p Value
Medications being taken at home
Aspirin 1,884 892 (47.3) 811 (46.8) 81 (54) 0.1051
Clopidogrel 1,883 303 (16.1) 272 (15.7) 31 (20.7) 0.1311
Warfarin 1,884 151 (8) 147 (8.5) 4 (2.7) 0.0075
Beta-blocker 1,883 791 (42) 722 (41.7) 69 (46) 0.3024
ACE inhibitor 1,882 800 (42.5) 733 (42.3) 67 (44.7) 0.6058
Calcium channel blocker 1,882 384 (20.4) 354 (20.4) 30 (20) 1.0000
Statins 1,883 814 (43.2) 737 (42.5) 77 (51.3) 0.0393
Diuretics 1,884 556 (29.5) 517 (29.8) 39 (26) 0.3517
Digoxin 1,884 50 (2.7) 47 (2.7) 3 (2) 0.7936
Aldosterone inhibitor 1,883 24 (1.3) 24 (1.4) 0 (0) 0.2527
Antiarrhythmic agents 1,883 49 (2.6) 47 (2.7) 2 (1.3) 0.4271
Analgesics 1,884 551 (29.2) 516 (29.8) 35 (23.3) 0.1115
Nitroglycerine 1,884 428 (22.7) 395 (22.8) 33 (22) 0.9191
Antibiotics 1,884 80 (4.2) 76 (4.4) 4 (2.7) 0.4020
Biomarker (median [IQR])
Copeptin (pmol/l) 1,967 9.7 [2.5–19.0] 9.2 [2.5–17.2] 19.9 [9.2–63.5] <0.0001
cTnI (ng/l) 1,967 3 [3–18] 3 [3–13] 181 [55–825] <0.0001
Values are mean  SD, median [25%–75% percentile], or n (%) and compared with Student t test, Kruskal-Wallis rank sum test, or the Pearson chi-square test (categorical variables). *Actual total number by
diagnostic subgroup may be lower for variables with missing data.
AICD ¼ automated implantable cardioverter-deﬁbrillator; ACE ¼ angiotensin-converting enzyme; AMI ¼ acute myocardial infarction; BMI ¼ body mass index; BP ¼ blood pressure; CAD ¼ coronary artery
disease; COPD ¼ chronic obstructive pulmonary disease; cTnI ¼ cardiac troponin I; IQR ¼ interquartile range.
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155cTnI negative.” Patients diagnosed with STEMI were
considered correctly diagnosed. Using this cTnI plus ECG
approach resulted in an NPV of 97.5% (95% CI: 96.5 to
98.3; 32 false-negative ﬁndings for NSTEMI), and a PPV
of 62.1% (95% CI: 54.4 to 69.2). Adding copeptin to this
algorithm provided a similar NPV of 97.3% (95% CI: 96.2
to 98.1; 35 false-negative ﬁnding for NSTEMI [p ¼ 0.75])
and a PPV of 64.8% (95% CI: 56.9 to 72.0; p ¼ 0.68)
(Table 2). Outcome of both diagnostic procedures differed
for only 12 patients (9 additionally correct and 3 additionallyFigure 1
Box Plot of Copeptin by
cTnI>/<99th Percentile and GSD
cTnI ¼ cardiac troponin I; GSD ¼ gold standard diagnosis; NSTEMI ¼ non–ST
elevation myocardial infarction; STEMI ¼ ST-segment elevation myocardial
infarction.wrong using the algorithm including copeptin; p ¼ 0.14,
McNemar’s chi-square test).
The main reason for the relatively high rate of false-
negative ﬁndings for the serial cTnI algorithm was that
the rise or fall of cTnI was not observable while looking at 0-
and 6-h data only; that is, the cTnI change was apparent
only if all available blood draws were included (n ¼ 21). For
the 11 remaining false-negative results, differences between
local laboratory results and cTnI were responsible: for the
majority (n ¼ 7), small absolute differences around the 99th
percentiles between the local laboratory results (used for gold
standard diagnosis) and central laboratory results (used for
evaluation) were responsible. For 4 patients, no obvious
reason could be identiﬁed.
In total, 503 patients were without a cTnI value at 6 h. Of
those, 10 were diagnosed with STEMI (2%) and 6 with
NSTEMI (1%). The proportion of STEMI was therefore
comparable to that in the overall population (2%), whereas
the proportion of NSTEMI was substantially lower (6% of
all patients). Of the 1,464 patients with a cTnI value at 6 h,
30 were diagnosed with STEMI (2%) and 110 with
NSTEMI (7.5%). The proportion with STEMI was
therefore comparable to that in the overall population (2%),
whereas the proportion with NSTEMI was slightly higher
(6% of all patients). Therefore, missing values of cTnI at
6 h seem to be due to both early rule-out (low NSTEMI
rate) and rule-in (equal STEMI rate), as well as missing
at random (NSTEMIs did occur, and data at other time
points were available: 376 of 503 had a nonmissing cTnI
at 2 h; 58 of 503 had a nonmissing cTnI at 24 h).
All-cause mortality within 180 days. At the 180-day
follow-up, 36 patients had died (1.8%; estimated 180-day
Figure 2 Biomarker Kinetics by AMI Diagnosis
Median copeptin (solid lines) and cTnI (dashed lines) concentrations by time since symptom onset and GSD (acute myocardial infarction [AMI] in blue, patients diagnosed with
other disease in green). Analysis based on data from blood draws at 0, 2, 6, and 24 h. Other abbreviation as in Figure 1.
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156survival rate 98.1% [95% CI: 97.4 to 98.7]). Median
copeptin and cTnI concentrations were lower in patients
who survived compared with those who died (9.5 pmol/l
[IQR: <5 to 18.4] vs. 45.8 pmol/l [IQR: 15.8 to 102.5] forFigure 3 Primary Endpoint
Patient distribution according to initial electrocardiogram (ECG), cTnI (cutoff 99th percenti
that STEMI patients will be identiﬁed by using ECG, sensitivity was 92.2% (95% conﬁden
identify NSTEMI patients. Therefore, negative predictive value (NPV) for copeptin levels <
predictive value (PPV) for patients with a positive cTnI or positive copeptin for NSTEMI is 1
with a negative cTnI value have an elevated copeptin value. For a ﬁnal diagnosis of AMI,
measurement. Conversely, patients negative for both copeptin and cTnI are assumed tocopeptin and <3 ng/l [IQR: <3 to 17] vs. 50 ng/l [IQR: 20
to 140] for cTnI; both p < 0.0001).
Both abnormal copeptin and cTnI levels were pre-
dictors of death (chi-square test 39.4 and 33.7, respectivelyle; 40 ng/L), and copeptin (cutoff 14 pmol/L) status at presentation (0 h). Assuming
ce interval [CI]: 85.9 to 95.9) and speciﬁcity was 62.6% (95% CI: 60.4 to 64.8) to
14 pmol/L and cTnI levels <40 ng/L is 99.2% (95% CI: 98.5 to 99.6). The positive
3.6% (95% CI: 11.4 to 16.2). In absolute numbers, 10 (53%) of 19 NSTEMI patients
patients either cTnI or copeptin positive are assumed to undergo a second cTnI
be ruled out of having an AMI. Other abbreviations as in Figures 1 and 2.
Figure 4 Addition of Copeptin to VAS
Visual analog scale (VAS) scores reﬂect the estimated risk for AMI determined in the emergency department after the ﬁrst cTnI measurement. VAS scores were categorized as
low risk (0% to 5%), intermediate risk (5% to 25%), and high risk (>25%). Bars represent observed risk of AMI in the study. Of 466 patients with VAS 5% to 25%, 294 (63%) had
a copeptin level <14 pmol/l and an AMI risk comparable to that of patients with VAS 0% to 5% (observed AMI risk 2% for both). Other abbreviations as in Figures 1 and 2.
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157[p < 0.0001 for both]; c index 0.784 and 0.800, respectively).
Both were independent of age and each other, and provided
additional predictive value (all p < 0.0001). Copeptin and
cTnI combined (as continuous variables) resulted in a chi-
square test of 59.2 and a c index of 0.842 (p < 0.0001).
Figure 5 illustrates the added value of copeptin with cTnI.
Copeptin was particularly strong for short-term prediction of
death. For outcome prediction at 30 days (n ¼ 13 deaths;
survival rate 99.3%), copeptin was associated with outcome,
with a chi-square test of 29.2 and a c index of 0.872, and
cTnI had a chi-square test of 13.7 and a c index of 0.828.
Both markers were independent of each other and combiningTable 2
Summary of the Primary Hypothesis: the Diagnostic Perform
a Negative Troponin in Conjunction With a Negative Copept
NSTEMI Prediction
Performance Based on First Blood Draw (plus EC
Guideline
(no rule out)
Troponin
Negative
Negative Tro
and Copep
NPV – 98.8 99.2
Sensitivity – 79.5 92.2
PPV – 34.5 13.6
Speciﬁcity – 89.8 62.6
False- negative NSTEMI (n) – 19 9
Total rule out, t ¼ 0 h (%) 0 (0%) 1,658 (84%) 1,143 (58
For comparison, we also included results for early rule out based on a negative cTnI at 0 h. First, we fo
performance of the full diagnostic procedures (after second blood draw). Negative predictive value (NPV),
ﬁrst draw and with serial troponin draws. Patients diagnosed as having ST-segment elevation myocard
cardiogram [ECG] only, and biomarker data were not taken into account for those). Therefore, NPV reﬂects
infarction can never be incorrect. None of the false-negative rates or the NPVs differed signiﬁcantly (allthem provided signiﬁcant added value (p ¼ 0.01 for added
value of cTnI, p< 0.0001 for added value of copeptin) (Fig. 6).
Discussion
The early differential diagnosis of acute chest pain is 1 of
the major clinical challenges in the ED. Although it is
mandatory to correctly identify those patients with AMI,
the vast majority of patients presenting with the symptoms
suggestive of ACS do not have AMI. In CHOPIN, 1 of the
largest multicenter studies on consecutive patients with chest
pain, only approximately 8% had a ﬁnal gold standardance of the Current Guideline (no rule out at 0 h) Versus
in for Early Rule Out
G) Performance of Full Diagnostic Procedure (after second blood draw)
ponin
tin Guideline
Troponin
Negative
Negative Troponin
and Copeptin
97.5 96.8 97.3
77.1 70.0 75.0
62.1 68.1 64.8
95.0 96.5 95.7
32 42 35
%) 0 (0%) 1,658 (84%) 1,143 (58%)
cused on the safety of the early rule out (results based on ﬁrst draw); second, we compared the
sensitivity, positive predictive value (PPV), and speciﬁcity are shown for this combination on both the
ial infarction were considered correctly diagnosed (i.e., diagnostic decision was based on electro-
non–ST elevation myocardial infarction (NSTEMI) results, because ST-segment elevation myocardial
p > 0.1).
Figure 6 Time-Dependent AUC for Survival to 180 Days
Area under the receiver-operating characteristic curve (AUC) for survival to 90 days
for copeptin (green), cTnI (blue), age (red), and the combination of copeptin and
cTnI (purple). Curves smoothed by a locally weighted polynomial regression;
horizontal lines at 30 and 90 days after presentation. Time-dependent receiver-
operating characteristic curves and time-dependent AUC values were determined
from censored survival data by using the Kaplan-Meier method. Copeptin was
particularly strong for short-term mortality prediction (<30 days), whereas cTnI was
stronger for long-term outcome prediction (>60 days).
Figure 5
Kaplan-Meier Plot Illustrating Added Value of
Copeptin in Addition to cTnI
Outcome is all-cause mortality within 180 days after presentation. Cutoff for cTnI
was the 99th percentile (40 ng/l); the cutoff for copeptin was third quartile
(19 pmol/l). Estimated survival rates were 99.5% (95% CI: 99.0 to 99.8) if both
biomarkers were below the cutoff and 90.0% (95% CI: 83.7 to 94.0) if both were
above the cutoff. With both copeptin and cTnI negative as reference group, the
hazard ratio (HR) for elevated copeptin levels but normal cTnI values was 6.3 (95%
CI: 2.3 to 17.2); HR for elevated cTnI but low copeptin was 8.1 (95% CI: 2.6 to
25.1); HR for both biomarkers above the deﬁned cutoff points was 22.7 (95% CI:
8.7 to 59.1) (all p < 0.01). Other abbreviations as in Figures 1 and 3.
Maisel et al. JACC Vol. 62, No. 2, 2013
The CHOPIN Trial: Copeptin in Early Detection of AMI July 9, 2013:150–60
158diagnosis of AMI (STEMI and NSTEMI), whereas >60%
had a noncardiac origin of their symptoms. According to
current guidelines, the management of suspected ACS
involves serial troponin measurements and monitoring over
many hours, which is a logistic challenge and a ﬁnancial
burden for already overcrowded EDs and hospitals.
If the ED physicians follow the current guideline recom-
mendations, all patients with a nondiagnostic ECG require an
ED stay of at least 3 to 6 h or admission to the hospital to rule
out an AMI. The present study shows that adding copeptin
allowed 58% of all patients with nondiagnostic ECG to be
ruled out for anAMI,whereas the number of undetectedAMI
cases only increased by 0.2% (from 32 to 35 of 1,967 patients).
Assuming a 3-h delay before the second cTnI is determined,
the availability of copeptin at baselinewould reduce the time to
decision for AMI diagnosis from an average of 3 to 1.8 h (43%
reduction). The clinical beneﬁt seems to be most prominent
in those patients with an intermediate risk of AMI (5% to
25%), as assessed by ED physicians. A low copeptin level in
these patients (<14 pmol/l) identiﬁes a subset with a risk
comparable to thosewho presentwith a low pretest probability
(<5%) for AMI. There is particular synergism between
a low pretest probability of AMI and nonelevated copeptin
values. Most (72%) of the AMIs detected who had normal
copeptin values were in those whowere not low risk. Copeptin
is the glycosylated, 39-amino-acid-long C-terminal part of
pro-AVP and is released together with AVP during precursor
processing. In contrast to AVP, copeptin is very stable in theserumor plasma at room temperature, and is easy and robust to
measure (2). An increase in copeptin concentrations after
AMI was ﬁrst reported by Khan et al. (4), with the highest
values reported onday 1 and a subsequent decline over the next
2 to 5 days. Copeptin concentrations were higher in patients
who died or were readmitted with heart failure compared with
event-free survivors. This ﬁnding led to 2 independent studies
examining the potential role of copeptin in the diagnosis of
AMI. The ﬁrst, by Reichlin et al. (5), evaluated the contri-
bution of copeptin to the management of 487 consecutive
patients with chest pain presenting to the ED. In those
patients with the ﬁnal gold standard diagnosis of AMI (17%),
copeptin concentrations were already elevated 4 h after the
onset of symptoms, at a time when troponin T was still
undetectable in many patients. As copeptin concentrations
declined, and troponin concentrations increased, these
distinct kinetics resulted in an additive value of both markers
for the diagnosis of AMI. The AUC of troponin alone in the
ﬁrst blood sample taken in the ED was 0.86, and increased to
0.97 by adding copeptin. Using this double marker approach,
a negative troponin and copeptin <14 pmol/l at presentation
allowed AMI to be ruled out, with an NPV >99%. A second
study conﬁrmed these ﬁndings and demonstrated that the
combined measurement of copeptin and troponin T in the
ﬁrst blood sample improved the c index from0.85 for troponin
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159T alone to 0.94 for a combination of copeptin and troponin T
(6). The effect was particularly prominent in patients pre-
senting within 3 h after symptom onset. In this group, the
combination increased the c index from 0.77 to 0.91. Gu et al.
(10) have demonstrated that copeptin peaks within the ﬁrst
hour after symptom onset, falling to normal ranges within the
ﬁrst day.
CHOPIN is the ﬁrst evaluation of copeptin in a US
cohort of a trial prospectively designed with predeﬁned
cutoff points to speciﬁcally evaluate NPV for rule out of
NSTEMI. In addition, CHOPIN is the largest trial of this
type to date. This large, multicenter trial conﬁrms that the
combination of a negative troponin and negative copeptin
value on presentation allows the rule out of AMI with an
NPV >99%. It is important to remember that a large part of
the NPV is contributed by troponin. Thus, using an
analytically sensitive troponin assay, in combination with
copeptin, will likely lead to an even higher NPV than the
less sensitive troponin assay used here. Other reports on
a direct comparison of high-sensitive troponin assays and
copeptin conﬁrm the additive effect reported in this study
(11). This is true for patients presenting early after symptom
onset, and it is likely that this added beneﬁt of copeptin
may be lost for patients who present late. Although copeptin
is a relatively new biomarker, it is an excellent surrogate
for AVP, which has been shown to also be elevated in
AMI (12,13). However, based on the complexity of AVP
measurements, this observation has never been clinically
relevant for diagnosis. In a sheep model of AMI, the peak
response of AVP occurred at 40 min after embolization,
and AVP was elevated for >12 h (14). But despite the very
early rise of AVP (and other hormones related to stress
response), none of these markers was followed up as a
potential candidate for the diagnosis of AMI due to severe
limitations in the measurement of these hormones. Neither
AVP nor adrenocorticotropic hormone is available as a rapid
and sensitive assay that would allow a fast enough “vein-to-
brain time” to inﬂuence the early ED diagnosis. Although
cortisol measurements are readily available, diurnal variation
makes them of less value.
There are several hypotheses to explain the rapid release of
AVP/copeptin after AMI. A likely explanation is that AVP
responds rapidly as part of the endocrine stress axis, resulting
in release of adrenocorticotropic hormone and cortisol.
Copeptin is believed to be a rapid and immediate biomarker
of the individual stress response (15). An alternative trigger
of AVP/copeptin secretion from the posterior pituitary could
be baroreceptor stimulation by the threat of hypotension as
a result of the AMI or direct damage to the cardiac baro-
receptors. The latter possibility is supported by the fact that
the highest copeptin elevation after AMI is seen in patients
with STEMI (5). Because copeptin is elevated in many
clinical states in which endocrinologic stress signals are
present, it will have low speciﬁcity for an individual disease
such as myocardial infarction, however; because myocardial
infarctions present with activation of the hypothalamic stressaxis, copeptin biomarkers demonstrate good sensitivity for
the disease state.
A second important result of the present study is the
prognostic role of copeptin. Voors et al. (16) demonstrated
that copeptin is a strong marker for mortality and
morbidity in patients with heart failure after AMI. Kelly
et al. (17) reported an association of copeptin with the
degree of left ventricular remodeling after AMI. These
observations were strengthened by the increased risk of
elevated copeptin concentrations and clinical heart failure
in those patients. This risk stratiﬁcation at an early stage
after AMI remains important and may be useful for
selecting treatment regimens in the future, such as the use
of AVP receptor antagonists (the “vaptan” class of drugs).
Reports on these drugs have been conducted for congestive
heart failure (18,19), but no study has yet examined the use
of vaptans in humans after AMI. Only animal data are
available on the improved cardiac hemodynamics after
administration of conivaptan (20). In addition, these data
suggest that even if AMI is excluded, some scrutiny to
determine the etiology of the elevated copeptin level is
likely warranted.
The independent prognostic information provided by
applying copeptin and troponin values was also seen in
a recent study of patients with heart failure treated in an
outpatient clinic (21). This study found that copeptin and
cardiac troponin T elevations, alone and in combination, are
powerful predictors of death and hospitalization. The inves-
tigators suggest that simultaneous assessment of myocardial
damage and the activated vasopressin system might be
of prognostic relevance. The prognostic role of copeptin in
congestive heart failure has been reported by others as
well (22–25).
Study limitations. Our data conﬁrmed that copeptin may
have clinical value if the early rule out of AMI is opera-
tionally of beneﬁt to the clinicians or hospital. However, if
the resources in a given institution are not limiting, then the
value of the time saved by more rapid diagnosis provided by
copeptin may be marginal. Whether the more expedient rule
out of AMI can improve the diagnostic performance for
other diseases in the differential diagnosis is beyond the
scope of the present report and would likely need to be
demonstrated in an interventional study. Due to the broad
heterogeneity of non-AMI diagnoses in patients presenting
with chest pain, this might be very difﬁcult to demonstrate
in a trial. Copeptin seems to provide added predictive value
on top of cTn, particularly for short-term prognosis.
However, the clinical relevance of this prognostic informa-
tion remains to be demonstrated. A signiﬁcant proportion of
patients had no second blood draw to determine troponin
levels as required by the guideline. Therefore, there is the
potential risk that this may bias the results evaluating serial
blood draws. Finally, the present analysis does not evaluate
copeptin in relation to a highly sensitive cTn with greater
precision around the rule-out cutoff. This may change the
added beneﬁt of copeptin.
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160Conclusions
This large multicenter trial suggests that the combination of
copeptin and troponin at the time of presentation provides
an NPV strong enough to avoid serial testing past 3 h and
hence improves medical decision making in patients with
chest pain presenting to the ED. Future research should
investigate the cost savings to EDs through use of such
a strategy.
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APPENDIX
For a detailed description of the study population and protocol, please see
the online version of this article.
